PA Request Criteria





226942

00-000000000

ACTION REQUIRED: Submit supporting documentation

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patient Name: Patient ID: Patient Group No:		NDW.	Date: Patient Date Of Birth: Patient Phone:	3/31/2025 Physician Name:	
Ph	ysician Office Address:	NPI#:		Specialty: Physician Office Telephone	
	ug Name (specify drug)				
	antity:		Streng	- th:	
			Expected Length of Therapy:		
	agnosis:		_ ICD Code:		
Со					
Ple 1.	ease check the appropriat What is the diagnosis?	e answer for each applical	ble question.		
	Hereditary angioedem laboratory testing (If c	na (HAE) with C1 inhibitor de hecked, go to 2)	eficiency or dysfunction confirmed by		
	Hereditary angioedem (If checked, go to 3)				
	Other, please specify.				
2.	REQUIRED: For any an	onditions does the patient ha swer, attach laboratory test o unctional and antigenic prote	ave at the time of diagnosis? ACTION or medical record documentation ein levels.		
	A C1 inhibitor (C1-INI laboratory performing	H) antigenic level below the lethe test (If checked, go to 4)	ower limit of normal as defined by the)		
	(functional C1-INH les	(C1-INH) antigenic level and as than 50% or C1-INH funct the laboratory performing the	d a low C1-INH functional level tional level below the lower limit of e test) (If checked, go to 4)		
	Other, please specify.	(If checked, no further ques	stions)		
	ACTION REQUIRED:	Submit supporting documer	ntation		
3.	REQUIRED: For any an confirming normal C1 in medical record documer (KNG1), heparan sulfate (MYOF) gene mutation to	swer, attach laboratory test on hibitor. Based on the answer tation confirming F12, angionally consumers and confirming F12.	ave at the time of diagnosis? ACTION or medical record documentation reprovided, attach genetic test or oppoietin-1, plasminogen, kininogen-1 sferase 6 (HS3ST6), or myoferlin ning family history of angioedema and antihistamine therapy.		
		6 (HS3ST6), or myoferlin (M	NG1), heparan sulfate-glucosamine YOF) gene mutation as confirmed by		
	therapy (i.e., cetirizine		to a trial of high-dose antihistamine uivalent) for at least one month AND o 4)		
	Other, please specify.	(If checked, no further ques	stions)		

Γ				
4.	Is the requested medication being used for the treatment of acute hereditary angioedema (HAE) attacks?	Y	N	
5.	Will the requested medication be used in combination with any other medication used for treatment of acute hereditary angioedema (HAE) attacks (e.g., Berinert, Firazyr, Kalbitor)?	Y	N	
6.	Have other causes of angioedema been ruled out (e.g., angiotensin-converting enzyme inhibitor [ACE-I] induced angioedema, angioedema related to an estrogen-containing drug, allergic angioedema)?	Y	N	
7.	Is the requested medication being prescribed by or in consultation with a prescriber who specializes in the management of hereditary angioedema (HAE)?	Y	N	
8.	Has the patient previously received treatment with the requested medication?	Y	N	
9.	Has the patient experienced a reduction in severity and/or duration of acute attacks? ACTION REQUIRED: If Yes, attach supporting chart note(s) demonstrating a reduction in severity and/or duration of acute attacks. ACTION REQUIRED: Submit supporting documentation	Υ	N	
10.	Does the patient's attack frequency, attack severity, comorbid conditions and patient's quality of life warrant prophylactic therapy?	Y	N	
11.	Has prophylactic treatment been considered?	Y	N	
12.	Please provide a brief rationale as to why prophylactic treatment has not been considered. Please specify rationale. (If checked, no further questions)			
	Unknown (If checked, no further questions)			

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.